ALPS 6-K
Alps Group Inc (ALPS)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of June 2026
Commission File Number: 001-42915
Alps Group Inc
(Registrant’s Name)
Unit E-18-01 & E-18-02, Level 18, Icon Tower (East)
No. 1, Jalan 1/68F, Jalan Tun Razak
50400 Kuala Lumpur
Wilayah Persekutuan, Malaysia
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Information Contained in this Form 6-K Report
Attached hereto as Exhibit 99.1 is a press release dated June 9, 2026 issued by Alps Group Inc (the “Company”), announcing that its subsidiary, MyGenome Sdn. Bhd., has received accreditation for Whole Genome Sequencing under MS ISO 15189:2022.
Exhibits
| Exhibit No. | Description | |
| 99.1 | Press Release dated June 9, 2026 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alps Group Inc | ||
| Date: June 9, 2026 | By: | /s/ Dr. Tham Seng Kong |
| Name: | Dr. Tham Seng Kong | |
| Title: | Chief Executive Officer and Director | |
Exhibit 99.1
Alps Group Inc Expands MyGenome Accreditation to Include Whole Genome Sequencing Under MS ISO 15189:2022
MyGenome Joins a Limited Number of Southeast Asian Laboratories Delivering WGS Under Internationally Recognized Clinical Standards, Strengthening its Position in Southeast Asian Genomics
KUALA LUMPUR, Malaysia – June 9, 2026 – Alps Group Inc (“Alps” or “the Company”) (Nasdaq: ALPS), an integrated biotechnology platform headquartered in Malaysia, today announced that its subsidiary, MyGenome Sdn. Bhd. (“MyGenome”), has received accreditation for its Whole Genome Sequencing (“WGS”) under MS ISO 15189:2022.
MS ISO 15189:2022 is an internationally recognized clinical standard that sets rigorous requirements for quality and competence in medical laboratories. Unlike targeted genetic panels, WGS examines a patient’s complete DNA sequence, making accreditation at this level a meaningful technical distinction. The expanded accreditation confirms that MyGenome’s genomic data meets the accuracy, reproducibility, and reliability benchmarks required for clinical use, healthcare adoption, and integration into research programs, positioning MyGenome among a select group of genomics laboratories in Southeast Asia operating WGS under this standard.
This milestone provides additional validation for institutional partners and investors alike, demonstrating that MyGenome’s WGS process meets the compliance-grade infrastructure required for adoption in clinical and research settings, broadening Alps’ addressable market to include government-linked healthcare programs, cross-border partnerships, and institutional clients across the region.
“Expanding our MS ISO 15189:2022 accreditation scope to include Whole Genome Sequencing is a meaningful validation of the clinical infrastructure we are building,” said Dr. Tham Seng Kong, Executive Director and Group Chief Executive Officer of Alps Group Inc. “Accreditation at this level signals to hospitals, research institutions, and partners that our genomic data is globally credible, clinically actionable, and fit for interrogation across our broader ecosystem. This milestone advances our goal of making world-class genomics a reality for patients across Southeast Asia.”
To be added to the Alps Group Inc email distribution list, please email [email protected] with ALPS in the subject line.
About Alps Group Inc
Alps Group Inc is a revenue-generating integrated biotechnology platform headquartered in Malaysia, operating across cell manufacturing, molecular diagnostics, and clinical delivery. Alps leverages revenue from its commercial businesses to support its clinical pipeline development with a mission to make advanced precision medicine accessible and affordable across Southeast Asia.
Forward-Looking Statements
Certain statements in this press release may be considered to contain certain “forward-looking statements” within the meaning of “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “target,” “believe,” “expect,” “will,” “shall,” “may,” “anticipate,” “estimate,” “would,” “positioned,” “future,” “forecast,” “intend,” “plan,” “project” and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on the Company management’s current beliefs, expectations, and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict and many of which are outside of our control. Actual results and outcomes may differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements.
A further list and description of risks and uncertainties can be found in documents filed with the Securities and Exchange Commission (“SEC”) by the Company and other documents that we may file or furnish with the SEC, which you are encouraged to read. Any forward-looking statement made by us in this press release is based only on information currently available to the Company and speaks only as of the date on which it is made. The Company undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments, or otherwise, except as required by law.
Investor Relations Contact
Philip Carlson
KCSA Strategic Communications
Phone: 212.896.1233
Email: [email protected]